Replies to post #437960 on NorthWest Biotherapeutics Inc (NWBO)

[The Danish Dude]

There are two websites.

a) http://feinberg.northwestern.edu

This was holding the text

Faculty member engaged in activities such as speaking, advising, consulting, or providing educational programs for the following companies or other entities
Boehringer Ingelheim Pharmaceuticals, Inc. (Boehringer Ingelheim GmbH)
NorthWest Biotherapeutics Inc.
Zai Lab Limited

This was the one Adam Feuerstein linked to.

Then we have website two

b) https://www.practiceupdate.com/author/roger-stupp/12

Dr. Stupp serves as an advisor to Celularity Inc, GT Medical Technology Inc, and DNAtrix Inc, Northwest Biotherapeutics Inc and several non-clinical stage biotech companies.

That text occured sometime inbetween November 5th. 2019 and September 26th. 2020.

On Ihub, it was mentioned that Stupp has served on ONE-TIME advisory boards for NWBO.

This article is from 2019

https://cancernetwork.com/view/newly-diagnosed-glioblastoma-review-clinical-management

"Dr. Stupp receives travel support from NovoCure; he also served on one-time advisory boards for Boehringer Ingelheim, Celgene, and Northwest Biotherapeutics."

I don't know about Stupps one-time advisory board jobs for Northwest 2018/19.

PracticeUpdate was updated sometime in 2020 with his advisor capability and it wasn't in 2018 and 2019.

[Nick119]

For sure - I think that may be a potential scenario AE. The case in the matter with Adam Feurenstein is that he is using diversion tactics stating that this is old news, which it is not. Until today, the vast majority of people were unaware of any relationship between Dr. Stupp and NWBO.

[exwannabe]

Nick:Our great friend, AF, alleges that Stupp started his relationship with Nwbo in '18.My batteryless clock is right twice a day. Maybe after Stupp read the 6/1/18 blinded data paper, he and LP started talking about him have an advisory role. Purely a speculation on my part.

Per this paper we know he had a paper published in 3/2019 that disclosed the relationship.

The paper was likely submitted prior to taht. And the one time advice would have been some time prior to that.

Very likely 2018.

As far as changing his mind on reading the paper, why did he publicly assert the paper was a bust for lack of data?